medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2018, Number 05

<< Back Next >>

Ginecol Obstet Mex 2018; 86 (05)

Threats to the safety of the patient due to the delivery management with oxytocin. Experience in a public hospital in Lima, Peru

Juárez-Coello P

Language: Spanish
References: 70
Page: 313-318
PDF size: 220.26 Kb.


ABSTRACT

Objective: Identify the threats to the safety of the patient in the practice of conducting labor with oxytocin and maternal and perinatal outcomes in a public tertiary hospital in Lima, during 2016.
Materials and Methods: Quantitative, descriptive, retrospective and crosssectional. A total 112 pregnants’ medical histories were review who underwent augmentation of labour with oxytocin. Inclusion criteria’s: term gestation, hospitalization with a 4 cm dilatation, fetuses in cephalic presentation. Exclusion criteria’s: patients with previous or intercurrent pathologies to pregnancy.
Results: The augmentation with oxytocin made in pregnant women without alterations in labor (29.5%; n = 33). The main type childbirth was vaginal delivery (73.2%; n = 82) and of the group that underwent cesarean section, the most usual reason was cephalopelvic disproportion (56.7%; n = 17). Obstetric complications were observed (25%; n = 28), of this group the main was postpartum hemorrhage (46.4%; n = 13). The weight of the newborns oscillated between 3401 ± 394 g, 93.7% and 96.4% obtained an Apgar 10 to 7 at the 1st and 5th minute respectively.
Conclusions: The threats to the safety of the patient identified were the practice of augmentation of labor with oxytocin in pregnant women without alterations in labor and in pregnant women with cephalopelvic disproportion, although it is a contraindication to the procedure.


REFERENCES

  1. Organización Mundial de la Salud. Marco Conceptual de la Clasificación Internacional para la Seguridad del Paciente. Ginebra: OMS, 2009; 103. www.who.int/patientsafety/ implementation/icps/icps_full_report_es.pdf

  2. Organización Mundial de la Salud. Soluciones para la seguridad del paciente. Ginebra: OMS, 2007. http://www. who.int/patientsafety/solutions/patientsafety/Patient- SolutionsSPANISH.pdf

  3. Eslamian J, Taheri F, Bahrami M, Mojdeh S. Assessing the nursing error rate and related factors from the view of nursing staff. Iran J Nurs Midwifery Res. 2010 Dec;15 (Suppl 1):272-77.

  4. Organización Mundial de la Salud. Recomendaciones de la OMS para la conducción del trabajo de parto. Ginebra: OMS, 2015; 6. www.who.int/topics/maternal_health/ directrices_OMS_parto_es.pdf

  5. López-Ramírez CE, Arámbula-Almanza J, Camarena-Pulido EE. Oxitocina, la hormona que todos utilizan y que pocos conocen. Ginecol Obstet Mex 2014; 82:472-482.

  6. Buckley S. Executive Summary of Hormonal Physiology of Childbearing: Evidence and Implications for Women, Babies, and Maternity. Care J Perinat Educ. 2015; 24(3): 145-153. doi: 10.1891/1058-1243.24.3.145.

  7. Bernitz S, Øian P, Rolland R, Sandvik L, Blix E. Oxytocin and dystocia as risk factors for adverse birth outcomes: A cohort of low risk nulliparous women. Midwifery 2014; 30(3):364- 70. doi.org/10.1016/j.midw.2013.03.010.

  8. Selin L, Almström E, Wallin G, Berg M. Use and abuse of oxytocin for augmentation of labor. Acta Obstet Gynecol Scand. 2009; 88(12): 1352–1357. doi. org/10.3109/00016340903358812.

  9. Brhlikova P, Jeffery P, Bhatia G, Khurana S. Intrapartum Oxytocin (Mis)use in South Asia. Journal of Health Studies. 2009; 2(1):33-50.

  10. Leal M, Esteves A, Soares R, Theme M, Bastos M, Nakamura M, et al. Intervenções obstétricas durante o trabalho de parto e parto em mulheres brasileiras de risco habitual. Cad. Saúde Pública [en línea] 2014; 30(1):17-32. dx.doi. org/10.1590/0102-311X00151513

  11. Valdez R, Hidalgo E, Mojarro M, Arenas L. Nueva evidencia a un viejo problema: el abuso de las mujeres en las salas de parto. CONAMED [en línea] 2013; 18(1): 14-20. Dirección URL: < http://www.dgdi-conamed.salud.gob. mx/ojs-conamed/index.php/revconamed/article/view/96 > (Consulta: agosto 2017)

  12. Paredes G. “Intervención del personal de enfermería, relacionado con el manejo de la oxitocina en la segunda etapa de la labor de parto en el centro obstétrico del Hospital Provincial Docente Ambato, durante el periodo agosto 2014 – enero 2015.” [Tesis] Ambato: Universidad Técnica de Ambato; 2015

  13. Instituto Nacional Materno Perinatal. Guías de Práctica Clínica y de Procedimientos en Obstetricia y Perinatología. Lima: INMP, 2010; 272-275. Dirección URL: (Consulta: abril 2018)

  14. Ministerio de Salud. Guía de Práctica Clínica para la Atención de Emergencias Obstétricas según nivel de capacidad resolutiva del Ministerio de Salud del Perú. Lima: MINSA; 2007; 91-96. Dirección URL: (Consulta: abril 2018)

  15. Ekelin M, Svensson J, Evehammar S, Kvist L. Sense and sensibility: Swedish midwives' ambiguity to the use of synthetic oxytocin for labour augmentation. Midwifery. 2015; 31(3):36-42. doi: 10.1016/j.midw.2014.12.006.

  16. Bugg GJ, Siddiqui F, Thornton JG. Oxytocin versus no treatment or delayed treatment for slow progress in the first stage of spontaneous labour (Review). Cochrane Database of Systematic Reviews 2011; 7: CD007123.

  17. Buchanan S, Patterson J, Roberts C, Morris J, Ford J. Trends and morbidity associated with oxytocin use in labour in nulliparas at term. Aust N Z J Obstet Gynaecol. [en línea] 2011; 52: 173–178. doi: 10.1111/j.1479-828X.2011.01403.x.

  18. Hidalgo P, Hidalgo M, Rodríguez M. Estimulación del parto con oxitocina: efectos en los resultados obstétricos y neonatales. Rev Lat Am Enfermagem. 2016;24:e2744. doi: 10.1590/1518-8345.0765.2744.

  19. Althaus J, Petersen S, Driggers R, Cootauco A, Bienstock, Blakemore K. Cephalopelvic disproportion is associated with an altered uterine contraction shape in the active phase of labor. Am J Obstet Gynecol. 2006 Sep;195(3):739- 42. doi: 10.1016/j.ajog.2006.05.053.

  20. Grotegut C, Paglia M, Johnson L, Thames B, Andra J. Oxytocin exposure during labor among women with postpartum hemorrhage secondary to uterine atony. AJOG 2011; 204(1):56. doi: 10.1016/j.ajog.2010.08.023

  21. Premature rupture of membranes. Practice Bulletin No. 160. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016; 127e39-51.

  22. Green-top Guideline No. 44. Preterm Prelabour Rupture of Membranes. Royal College Obstetricians and Gynaecologists, 2010.

  23. Di Renzo GC, Cabero Roura L, Facchinetti F, Antsaklis A, Breborowicz G, Gratacos E, Husslein P, et al. Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth. J Matern Fetal Neonatal Med. 2011; 24:659-667.

  24. Berger T, Bernet V, El Alama S, et al. Perinatal care at the limit of viability between 22 and 26 completed weeks of gestation in Switzerland. Swiss Med Wkly. 2011;141:13280.

  25. Mastrolia SA, Erez O, Loverro G, Di Naro E. Ultrasonographic approach to diagnosis of fetal inflammatory response syndrome: a tool for at-risk fetuses? Am J Obstet Gynecol 2016;215(1): 9-20.

  26. Melamed N, Ben-Haroush A, Pardo J, et al. Expectant management of preterm premature rupture of membranes: is it all about gestational age? Am J Obstet Gynecol 2011; 204:48. e1-8.

  27. American College of Obstetricians and Gynecologists Practice Bulletin No. 97. Fetal Lung Maturity. Obstet Gynecol. 2008;112(3):717-26.

  28. Chen Franck CK, Dudenhausen JW. Comparison of two rapid strip tests based on IGFBP-1 and PAMG-1 for the detection of amniotic fluid. Am J Perinatol 2008;25:243-246.

  29. EI-Messidi A, Cameron A. Diagnosis of premature rupture of membranes: inspiration from the post and insights for the future. J Obstet Gynaecol Can 2010; 32:561-569.

  30. lbrahim A, Abdelazim Khaled M, Abdelrazak Mohamed Al-Kadi, et al. Fetal fibronectin (Quick Check fFN test) versus placental alpha microglobulin-i (AmniSure test) for detection of premature rupture of fetal membranes. Arch Gynecol Obstet. 2014;290:457-464.

  31. Neil PRL, Wallace EM. Is AmniSure useful in the management of women with prelabor rupture of the membranes? Aust N Z J Obstet Gynaecol. 2010 Dec;5(6):534-8.

  32. Martin JA, Hamilton BE, Ventura SJ, Osterman MI, Wilson EC, Mathews TJ. Births: final data for 2010. Nati Vital Stat Rep 2012;61(1):1-71.

  33. Melamed N, Shah J, Soraisham A, Yoon EW, Lee SK, Shah PS, et al. Association between antenatal corticosteroid administracion-to-bith interval and outcomes of preterm neonates. Obstet Gynecol 2015; 125:1317-1326.

  34. Asztalos E, Willan A, Murphy K, Matthews S, Ohlsson A, Saigal S, et al. Association between gestational age at birth, antenatal corticosteroids, and outcomes at 5 years: multiple courses of antenatal corticosteroids for preterm birth study at 5 years of age (MACS-5). BMC Pregnancy Childbirth 2014;14: 272.

  35. Crowther CA, McKinlay CJ, Middleton P, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Syst Rev 2015;(7):CD003935.

  36. Brownfoot FC, Gagliardi DI, Bain E. Middleton P, Crowther CA. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2013; (8): CD006764.

  37. Sotiriadis A, Tsiami A, Papatheodorou S, Baschat AA, Sarafidis K, Makrydimas G. Neurodevelopmental outcome after a single course of antenatal steroid in children born preterm: a systematic review and meta-analysis. Obstet Gynecol 2015;125:1385-96.

  38. Vidaeff AC. Risks and benefits of antenatal corticosteroid therapy prior to preterm birth in pregnancies complicated by fetal growth restriction. Perinatoloji Dergisi 2011;19(Suppl 1): S58-S62.

  39. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet 2008; 372:1319-27.

  40. Use of prophylactic antibiotics in labor and delivery. Practice Bulletin No. 120 American College of Obstetricians and Gynecologists. Obstet Gynecol 2011; 117:1472-83.

  41. Chapman E, Reveiz L, Illanes E, Bonfill CX. Antibiotic regimens for management of intra-amniotic infection. Cochrane Database Syst Rev. 2014;12:CD010976.

  42. Kenyon SI, Taylor DJ, Tarnow-Mordi W. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomized trial. ORACLE Collaborative Group. Lancet 2001;357:979-988.

  43. Rizzo G, Arduhi D, Romanhi C. Fetal Doppler echocardiography: principles, technique and reference limits. In: Arduini DRG, Romanhi C. eds. Fetal Cardiac function. New York: Parthenon Publishing, 1996; 33-41.

  44. Gotsch F, Romero R, Kusanovic JP, et al. The fetal inflammatory response syndrome. Clin Obstet Gynecol 2007;50:652-83.

  45. Romero R, Espinoza Jeri Gonçalves LF, et al. Fetal cardiac dysfunction in preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2004; 16:146-57.

  46. Gauthier DW, Meyer WJ, Bieniarz A. Biophysical profile as a predictor of amniotic fluid culture results. Obstet Gynecol 1992; 80:102-5.

  47. Romero R, Gómez R, Ghezzi F, et al. A fetal systemic inflammatory response is followed by the spontaneous onset of preterm parturition. Am J Obstet Gynecol 1998; 179:186-93.

  48. Eldem BW, Edwards JM, Cetta F. Quantitative assessment of fetal ventricular function: establishing normal values of the myocardial performance index in the fetus. Echocardiography 2001; 18:9-13.

  49. Ichizuka K, Matsuoka R, Hasegawa J, et al. The Tei Index for evaluation of fetal myocardial performance in sick fetuses. Early Hum Dev 2005; 81:273-9.

  50. Pellet AA, Tolar WG, Merwin DG, Kerut EK. The Tei Index: methodology and disease state values. Echocardiography 2004; 21: 669-72.

  51. Friedman D, Buyen J, Kim M, Glickstein JS. Fetal cardiac function assessed by Doppler myocardial performance index (Tei Index). Ultrasound Obstet Gynecol 2003; 21: 33-6.

  52. Sperling, RS, Newton, E, Gibbs, RS. Intraamniotic Infection in Low-Hirth-Weight Infants. J Infect Dis 1988; 157:113. https://doi.org/10.1093/infdis/157.1.113.

  53. Fishman SG, Gelber SE. Evidence for the clinical management of chorioamnionitis. Seminars in Fetal & Neonatal 2012; 17:46-50. https://doi.org/10.1016/j. siny.2011.09.002

  54. Ferguson MG, Rhodes PG, Morrison JC, Puckett CM. Clinical amniotic fluid infection and its effect on the neonate. Am J Obstet Gynecol 1995; 151:1058-61.

  55. Roussis P, Rosemond RL, Glass C, Boehm F. Preterm premature rupture of membranes: detection of infection. Am J Obstet Gynecol 1991; 165:1099-104.

  56. Hauth JC, Gilstrap LC, Hankins GD, Connor KD. Term maternal and neonatal complications of acute chorioamnionitis. Obstet Gynecol 1985; 66:59.

  57. Besnard EA, et al. Lecithin/sphingomyelin ratio and lamellar body count for fetal lung maturity: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013;169:177-183.

  58. Yarbrough ML, Grenache DG, Gronowski AM. Fetal lung maturity testing: the end of an era. Biomarkers in Medicine 2014; 8:509-515.

  59. Leung-Pineda V, Gronowski AM. Biomarker tests for fetal lung maturity. Biomark Med 2010; 4(6): 849-857.

  60. Gilstrap LC, Cox SM. Acute chorioamnionitis. Obstet Gynecol Clin North Am 1989; 16:373-379.

  61. Rouse DJ, Landon M, Leveno KJ, et al. The maternal fetal medicine units cesarean registry: chorioamnionitis at term and its duration e relationship to outcomes. Am J Obstet Gynecol 2004; 191(1):211-216.

  62. Centers for Disease Control and Prevention. Prevention of Perinatal Group B Streptoccal Disease. MMWR 2010;59(No. RR--10):1-18.

  63. Fishman SG, Gelber SE. Evidence for the clinical management of chorioamnionitis. https://doi.org/10.1016/j. siny.2011.09.002.

  64. Melamed N, Hadar E, Ben-Haroush A, Kaplan B, Yogev Y. Factors affecting the duration of the latency period in preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2009; 22:1051-6.

  65. Heath PT, Balfour GF, Tighe H, Verlander NQ, Lamagni TL, Efstratiou A, HPA GBS Working Group. Group B streptococcal disease in infants: a case control study. Archives of Disease in Chilhood 2008; 94 (9). http://dx.doi.org/10.1136/ adc.2008.148874

  66. The American College of Obstetricians and Gynecologists. Prevention of Early Onset-Group B Streptococcal Disease on Newborns. Committe Opinion. 2011

  67. Tita ATN, Andrews WW. Diagnosis and management of clinical chorioamnionitis. Clin Perinatol. 2010 June; 37(2): 339-354.

  68. Gibbs RS, Duff P. Progress in pathogenesis and management of clinical intraamniotic infection. Am J Obstet Gynecol. 1991;164(5 Pt 1):1317-1326.

  69. Laskin MD, Wendy L Whittle. Preterm premature rupture of membranes in the presence of cerclage: is the risk for intra-uterine infection and adverse neonatal outcome increased? The Journal of Maternal-Fetal & Neonatal Medicine. 2012; 5e424-428. https://doi.org/10.3109/14 767058.2011.569800

  70. lyean A, Garite TJ, Maurel K, et al. Removal vs retention of cerclage in preterm premature rupture of membranes: a randomized controlled trial. Am J Obstet Gynecol 2014; 211:399.e1-7.




2020     |     www.medigraphic.com